Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: A prospective, randomized, placebo-controlled study

European Journal of Endocrinology

Volumn 158, Issue 2, 2008, Pages 229-237

  van Geest, Rob J ^a,b   Sasim, Inna V ^a   Koppeschaar, Hans P F ^a   Kalmann, Rachel ^a   Stravers, Simone N ^a   Bijlsma, Ward R ^a   Mourits, Maarten P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; SOLVENT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DIPLOPIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG TOLERABILITY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE EDEMA; EYE MOVEMENT; EYELID RETRACTION; FACE EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERTENSION; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN; GRAVES DISEASE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38949154625     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0558     Document Type: Article

References (25)

1. Werner CS. Modification of the classification of the eye changes of Graves' disease: recommendations of the ad hoc committee of the American thyroid Association. Journal of Clinical Endocrinology and Metabolism 1977 44 203-204.
2. Rundle FF. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clinical Science 1945 5 177-194.
3. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A & Van der Gaag R. Effects of abnormal thyroid function on the severity of Graves' ophthalmopathy. Archives of Internal Medicine 1990 150 1098-1101.
4. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A & van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. British Journal of Ophthalmology 1989 73 639-644.
5. Mourits MP, Prummel MF, Wiersinga WM & Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology 1997 47 9-14.
6. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, Cavallacci G, Baschieri L & Pinchera A. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. Journal of Clinical Endocrinology and Metabolism 1983 58 1139-1144.
7. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G & Fenzi G. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. Journal of Endocrinological Investigation 2001 24 152-158.
8. Kahaly GJ, Pitz S, Hommel G & Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism 2005 90 5234-5240.
9. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A & Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. New England Journal of Medicine 1989 321 1349-1352.
10. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M & Hatt K. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988 297 1574-1578.
11. Marcocci C, Bartalena. L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M & Pinchera A. Comparison of effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of prospective, single-blind, randomized study. Journal of Clinical Endocrinology and Metabolism 2001 86 3562-3567.
12. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L & Wiersinga WM. Randomized, double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993 342 949-954.
13. Mourits MP, Van Kempen-Harteveld ML, Garcia-Garcia MB, Koppeschaar HPF, Tick L & Terwee CB. Radiotherapy for Graves' orbitopathy: randomized placebo-controlled study. Lancet 2000 355 1505-1509.
14. Mourits MP, Kalmann R & Sasim IV. Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy, Orbit 2001 20 275-280.
15. Dandonna P, Harward CWH & Mier A. Methylprednisolone and Graves' ophthalmopathy. BMJ 1989 16 415-422.
16. Guy J, Fagien S, Donovan J & Rubin M. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 1989 96 1048-1053.
17. Marino M, Morabito E, Altea MA, Ambrogini E, Oliveri F. Brunetto MR, Pollina LE, Campani D, Vitti P, Bartalena L, Pincheral A & Marcocci C. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. Journal of Endocrinological Investigation 2005 28 280-284.
18. Marino M, Morabito E, Brunetto MR, Bartalena L, Pincheral A & Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' opthalmopathy. Thyroid 2004 14 403-406.
19. Weissel M & Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000 10 521.
20. Mourits MP, Lombardo SH, van der Sluijs FA & Fenton S. Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves' patients. An exploratory study. Orbit 2004 23 161-168.
21. Mourits MP, Prummel MF, Wiersinga WM & Koornneef L. Measuring eye movement in Graves' ophthalmopathy. Ophthalmology 1994 101 1341-1346.
22. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E & Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine 1998 338 73-78.
23. Paridaens D, Hans K, Van Buitenen S & Mourits MP. The incidence of diplopia following coronal and translid orbital decompression in Graves' orbitopathy. Eye 1998 12 800-805.
24. Krassas GE & Boboridis K. Recent developments in the medical treatment of thyroid eye disease. Orbit 2006 25 117-122.
25. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L & Wiersinga WM. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. New England Journal of Medicine 1989 321 1353-1359.